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1. Introduction 
A new group of arachidonic acid metabolites, the 
leukotrienes [l-3] has been found to include the 
slow-reacting substance of anaphylaxis (SRS-A). 
SRS-A is a mediator in various hypersensitivity reac- 
tions, among these asthma [4]. The first slow reacting 
substance identified was leukotriene C+ which was 
isolated from incubations of murine mastocytoma 
cells with ionophore A23 187 and Lcysteine [ 5 -81. 
The 11 -truns-isomer of LTC4 was also formed as 
shown later by synthetic studies [9]. A metabolite of 
LTC,, S(S)-hydroxy-6(R)&cysteinylglycyl-7,9-trans- 
1 I ,14~~s~icosatetraenoic a id (leukotriene Da, 
LTD4) was originally detected in RBL-cells [lo]. 
LTC4 and LTD4 were also isolated from rat perito- 
nealcells [ll-131,andhumanlung [12,13].Partial 
support for the formation of LTD, in RBL-cells and 
in sensitized guinea-pig lung has also been reported 
from other laboratories [ 14- 16f. 
LTC4 was early proposed to be biosynthesized 
from arachidonic acid via 5(S)-hydroperoxy-6-trans- 
8,11,14ciseicosatetraenoic acid (5-HPETE) and the 
unstable allylic epoxide (5(S)-trans5,6_oxido-7,9- 
trans-I 1,14ciseicosatetraenoic acid (Ieukotriene Ad, 
LTA4)) (fig.1) [2,5]. The intermediate LTA4 [17] 
has been isolated from human PMNL [ 181 and shown 
to be converted into LTC4 in these cells [ 191. LTA4 
was also shown to be the precursor of 5@),12(R)- 
dihydroxy-6,8,10,14_eicosatetraenoic a id.(leuko- 
triene B4, LTB,) [20] which had been isolated 
together with compounds I, II, IV and V (fig.1) from 
rabbit PMNL 121,221 and from human PMNL where 
the ionophore A23187 enhanced the biosynthesis 
[23]. The ionophore also stimulates the formation of 
SRS in human leukocytes [24,25]. 
This paper concerns the identification of the SRS 
produced in human PMNL, when incubated with 
em” Artchidonic acid 
5-HETE 
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Fig-l. Leukotriene biosynthesis in human polymorphonu- 
clear leukocytes. Asterisk indicates that the exact stereo- 
chemistry of the double bonds has not been determined. 
ionophore A23 187, arachidonic acid and Lcysteine 
or glutathione. This SRS is shown to be composed of 
leukotriene Cq and 11 -trans-leukotriene C+ 
2. Materials and methods 
Arachidonic acid was purchased from Nu-Chek, 
MN, and ionophore A23 187 from Calbiochem- 
Behring, La Jolla, CA. Dextran T-500 was obtained 
from Pharmacia, Uppsala and Lymphoprep from 
Nyegaard, Oslo. FPL 557 12 was a kind gift from 
Fisons, Pharmaceut. Div., Loughborough and 
BW 7S5C (3-amino-l-~~~trifluoromethyl)-phenyl)” 
2-pyrazoline) from Dr F. Kuehl, Merck, Rahway, NJ. 
Soybean lipoxygenase type I (EC 1 .13 .l 1.12) was 
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purchased from Sigma, St Louis, MO. Synthetic 
LTCJ and 11 -trans-LTC4 were generously provided by 
Dr E. J. Corey, Harvard University, Cambridge, MA. 
2.1. Cell preparation 
Suspensions of human PMNL were prepared from 
concentrations of human leukocytes obtained upon 
blood component preparation at the Karolinska 
Hospital. The procedure outlined in [23] was fol- 
lowed, which implies centrifugation to remove plate- 
let rich plasma, dextran sedimentation to separate 
white cells from red cells, ammonium-chloride lysis of 
remaining red cells and finally gradient centrifugation 
in Lymphoprep to separate PMNL from other white 
cells. For large scale incubations the Lymphoprep 
centrifugation was omitted and the whole leukocyte 
fraction was used. 
2.2, Incubations 
Around 30 X lo8 cells suspended in 100 ml 
Dulbecco’s PBS buffer (pH 7.4) were warmed to 
37°C. L-Cysteine or reduced glutathione was added 
to a final concentration of 0.01 M. After 2 min, 
ethanol solutions of arachidonic acid and ionophore 
A23 187 were added to the cell-suspension to final 
concentrations of 15 PM and 5 FM, respectively. 
The amount of ethanol never exceeded 0.1%. After 
10 min the incubations were stopped by addition of 
400 ml ethanol. 
2.3. Isolation and purification 
The ethanol solution from the incubation was fil- 
tered, evaporated to dryness and dissolved in dilute 
NaOH. The pH was then adjusted to 12. After 30 min 
at 37’C the sample was neutralized to pH 6 and 
extracted by Amberlite XAD-8 (Rohm and Haas, 
Philadelphia, PA) utilizing a batch-column procedure. 
The sample was eluted with 80% ethanol from the 
XAD-8 column. To ihe ethanol extract was added 1 g 
SilicAR CC-7 (Mallinckrodt, St Louis, MO) and the 
solvent was evaporated to dryness. The sample, with 
silicic acid particles, was applied to a column packed 
with 4 g SilicAR CC-7 in methanol-ethyl acetate 
(10/90, v/v) and eluted first with 200 ml of the same 
solvent followed by 200 ml methanol. The methanol 
eluate was subjected to reverse-phase HPLC. 
2.4. High performance liquid chromatography 
(HPLC) 
Reverse phase HPLC was performed on Polygosil 
88 
60-10 Crs (10 X 500 mm) and Nucleosil 5 Cia 
(4.6 X 250 mm, Macherey-Nagel, Duren) using a 
Constametric III pump with a Rheodyne 7 125 injec- 
tor and a Spectromonitor III variable W-detector 
(LDC, Riviera Beach, FL). The solvent systems were 
methanol-water-acetic acid (70/30/0.1, by vol.) for 
the Polygosil column (flow rate 4.5 ml/min) and 
methanol-water-acetic acid (60/40/0.1, by vol.) for 
the Nucleosil column (flow rate 1 .O ml/min). The sol- 
vents were buffered to apparent pH 5.1 with ammo- 
nium hydroxide. The methanol eluate from the silicic 
acid column was chromatographed on the Polygosil 
column. The biologically active fractions were subse- 
quently rechromatographed on the Nucleosil column. 
2.5. Analytical methods 
Bioassay was performed on the isolated guinea-pig 
ileum in a 7 ml cuvette with Tyrode’s buffer con- 
taining atropine sulfate (1 0v6 M) and mepyramine 
maleate (10” M) as in [5]. Ultraviolet spectrum in 
the wavelength range 350-220 nm was obtained on a 
Cary 219 spectrophotometer (Varian, Palo Alto, CA). 
For incubation with soybean lipoxygenase, 2 nmol 
substrate were incubated with 50 pg enzyme in 
1 ml, 0.1 M phosphate buffer (pH 7.4 at 20°C) for 
30-45 min. Amino acid analyses were performed on 
a Beckman 12 1 M instrument after hydrolysis in 6 M 
HCl with 0.5% phenol at 110°C for 20 h. Norleucine 
(5 nmol) was added as internal reference. 
3. Results and discussion 
Human PMNL incubated with ionophore A23 187, 
arachidonic acid and L-cysteine produced two slow 
reacting substances. The presence of arachidonic acid 
and cysteine increased the amounts of ionophore- 
induced SRS several-fold, in accordance with earlier 
reports [26-281. In our experiments cysteine could 
be replaced by glutathione. 
The SRS produced in the incubations was isolated 
and purified by a procedure involving alkaline hydro- 
lysis, extraction by Amberlite XAD-8, silicic acid 
chromatography and two steps of reverse-phase 
HPLC. All SRS-activity was eluted in one single frac- 
tion, both in the XAD-8 and in the silicic acid chro- 
matography. On the first HPLC column (Polygosil 
Crs) two components with SRS-activity separated 
(fig.2). The major component (peak I) was eluted 
after 27 min and the minor product (peak II) appeared 
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Fig.2. Reverse-phase HPLC chromatogram of the products 
obtained from incubation of human PMNL with ionophore 
A23187, arachidonic acid and Lcysteine (ultraviolet 280 nm). 
The incubation was stopped with ethanol and the lipids were 
purified by chromatography on Amberlite XAD-8 resin fol- 
lowed by CC-7 silicic acid, before HPLC. The Polygosil 
C,,column was eluted with methanol/water/acetic acid, 
(70/30/0.1, by vol.) pH 5.1,4.5 ml/min. The insert shows the 
ultraviolet spectra of the two main products. 
after 3 1 min. The material in the two peaks were 
homogenous when rechromatographed on the 
Nucleosil Cl* column. They now appeared after 35 
and 41 min, respectively. 
The elution times of peak I on both HPLC col- 
umns were identical with that of synthetic LTC4. This 
was also shown by cochromatography on Nucleosil 
Cl8 of the material in peak I mixed with an equal 
amount of synthetic LTC4. The ultraviolet spectrum 
of compound 1 was identical with that of LTC$, with 
a maximum at 280 nm and shoulders at 270 and 
292 nm (fig.2). Both compound I and LTC4 gave 
identical results upon incubation with soybean lip- 
oxygenase. A spectral change to a new maximum at 
308 nm was seen, which indicated the formation of a 
conjugated tetraene. [5]. The amino acid composition 
of compound I and synthetic LTC4, determined after 
acid hydrolysis, was identical. In the guinea-pig ileum 
bioassay, compound I and synthetic LTC, showed 
essentially the same properties, judged by the con- 
tractile response, the relaxation after addition of 
FPL 5.5712 (lo-’ M), and the dose-response rela- 
tionship (fig.3). 
Cochromatography of the material in peak II 
mixed with an equal amount of synthetic 1 l-truns- 
LTCd showed one homogenous peak. The ultraviolet 
spectrum of compound II had a maximum at 278 nm, 
with shoulders at 268 and 290 nm, identical with that 
o Synthetic LTCI 
l Human PMNL SRS (compound I) 









Fig.3. Guinea-pig ileum bioassay on the two compounds 
obtained from incubation of human PMNL with ionophore 
A23 187, arachidonic acid and L-cysteine. The amounts admin- 
istered to the gut was estimated by ultraviolet absorption, 
assuming E = 40 000 for these compounds. 
of 1 l-truns-LTC4 (fig.2). Neither compound II nor 
11 -trans-LTC, was converted by soybean lipoxygen- 
ase, which indicated lack of the necessary 11,14&s 
diene structure [29]. 
Amino acid analysis of compound II gave the same 
results as for compound I, LTC4 and 1 1-frans-LTC+ 
Compound II was less active than LTC4 in the guinea- 
pig ileum assay (fig.3), which is in accordance with 
observations in [9]. 
Thus, compound I and compound II in these incu- 
bations were identical with LTC4 and 1 I-trans-LTC,, 
respectively. When the lipoxygenase inhibitor 
BW 755C was added to the incubations (10 pg/ml), 
none of these compounds could be detected [30]. 
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